Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Novartis' First-in-Class Biologic Psoriasis Treatment Approved in China

publication date: Apr 3, 2019

Novartis announced that China's NMPA approved Cosentyx® (secukinumab), a first-in-class biologic interleukin-17A (IL-17A) inhibitor for moderate-to-severe plaque psoriasis. Cosentyx, which is approved for adult patients who are candidates for systemic therapy or phototherapy, is the ninth new Novartis drug approved in China over the last two years. The company expects to bring ten more novel drugs to the China market during the next few years, including its Kymriah CAR-T treatment for cancer. Novartis expects China will become its third largest market. More details....

Stock Symbol: (NYSE: NVS)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital